{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:32Z","timestamp":1740144092243,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40261-024-01408-5","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T19:31:19Z","timestamp":1732822279000},"page":"961-974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Tofacitinib (Xeljanz\u00ae) in Europe: A Prescriber Survey"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8132-3882","authenticated-orcid":false,"given":"Joanne","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-6202","authenticated-orcid":false,"given":"Nana","family":"Koram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kofi","family":"Asomaning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8891-287X","authenticated-orcid":false,"given":"Lubna","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6079-1869","authenticated-orcid":false,"given":"Robert","family":"Massouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhan","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8128-2980","authenticated-orcid":false,"given":"Laura","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafia","family":"Bosan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-3273","authenticated-orcid":false,"given":"Krystal","family":"Cantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1408_CR1","unstructured":"European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module V: risk management systems (Rev 2). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf. Accessed 1 Mar 2024."},{"key":"1408_CR2","unstructured":"European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module XVI: risk minimisation measures: selection of tools and effectiveness indicators (Rev 2). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf. Accessed 1 Mar 2024."},{"key":"1408_CR3","unstructured":"European Parliament, Council of the European Union. Directive 2010\/84\/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001\/83\/EC on the community code relating to medicinal products for human use text with EEA relevance. 2010. https:\/\/data.europa.eu\/eli\/dir\/2010\/84\/oj. Accessed 1 Mar 2024."},{"key":"1408_CR4","unstructured":"Pfizer. Xeljanz\u00ae (tofacitinib citrate) receives marketing authorisation in the European Union for active psoriatic arthritis. 2018. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xeljanz_tofacitinib_citrate_receives_marketing_authorisation_in_the_european_union_for_active_psoriatic_arthritis-0. Accessed 1 Mar 2024."},{"key":"1408_CR5","unstructured":"Pfizer. Xeljanz\u00ae (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis (RA). 2017. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xeljanz_tofacitinib_citrate_receives_marketing_authorisation_in_the_european_union_for_the_treatment_of_moderate_to_severe_active_rheumatoid_arthritis_ra. Accessed 1 Mar 2024."},{"key":"1408_CR6","unstructured":"Pfizer. Xeljanz\u00ae (tofacitinib citrate) receives marketing authorization in the European Union for moderately to severely active ulcerative colitis. 2018. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xeljanz_tofacitinib_citrate_receives_marketing_authorization_in_the_european_union_for_moderately_to_severely_active_ulcerative_colitis-0. Accessed 1 Mar 2024."},{"key":"1408_CR7","unstructured":"European Medicines Agency. Xeljanz to be used with caution for all patients at high risk of blood clots. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/xeljanz-article-20-procedure-xeljanz-be-used-caution-all-patients-high-risk-blood-clots_en.pdf. Accessed 1 Mar 2024."},{"key":"1408_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"1408_CR9","unstructured":"European Medicines Agency. Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. 2019. https:\/\/www.ema.europa.eu\/en\/news\/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis. Accessed 1 Mar 2024."},{"key":"1408_CR10","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7\u201310 June 2021. 2021. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-june-2021. Accessed 21 Mar 2024."},{"key":"1408_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40290-019-00273-4","volume":"33","author":"J Lem","year":"2019","unstructured":"Lem J, Younus M, Aram JA, Moosavi S, Freivogel K, Lewis A, et al. Evaluation of the effectiveness of additional risk minimization measures for voriconazole in the EU: findings and lessons learned from a healthcare professional survey. Pharmaceut Med. 2019;33:121\u201333. https:\/\/doi.org\/10.1007\/s40290-019-00273-4.","journal-title":"Pharmaceut Med."},{"key":"1408_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40290-021-00380-1","volume":"35","author":"S Mayall","year":"2021","unstructured":"Mayall S, Kahlon R, Al-Dakkak I, Shen SW. Evaluating the effectiveness of apixaban additional risk minimisation measures using surveys in Europe. Pharm Med. 2021;35:123\u201335. https:\/\/doi.org\/10.1007\/s40290-021-00380-1.","journal-title":"Pharm Med."},{"key":"1408_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40264-018-0662-2","volume":"41","author":"W Landsberg","year":"2018","unstructured":"Landsberg W, Al-Dakkak I, Coppin-Renz A, Geis U, Peters-Strickland T, van Heumen E, et al. Effectiveness evaluation of additional risk minimization measures for adolescent use of aripiprazole in the European Union: results from a post-authorization safety study. Drug Saf. 2018;41:797\u2013806. https:\/\/doi.org\/10.1007\/s40264-018-0662-2.","journal-title":"Drug Saf"},{"key":"1408_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40290-019-00279-y","volume":"33","author":"LJ Zografos","year":"2019","unstructured":"Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, et al. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharm Med. 2019;33:219\u201333. https:\/\/doi.org\/10.1007\/s40290-019-00279-y.","journal-title":"Pharm Med."},{"key":"1408_CR15","unstructured":"Pfizer. A3921334 Non-interventional (NI) study protocol. 2022. https:\/\/catalogues.ema.europa.eu\/sites\/default\/files\/document_files\/A3921334_PROTOCOL-%20XELJANZ%20HCP%20SURVEY%20CLEAN_V3.0_28MAR2022.pdf. Accessed 4 Oct 2024."},{"key":"1408_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12872-017-0591-5","volume":"17","author":"JP Halcox","year":"2017","unstructured":"Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17:160. https:\/\/doi.org\/10.1186\/s12872-017-0591-5.","journal-title":"BMC Cardiovasc Disord"},{"key":"1408_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.rmed.2009.10.007","volume":"104","author":"CG L\u00f6fdahl","year":"2010","unstructured":"L\u00f6fdahl CG, Tilling B, Ekstr\u00f6m T, J\u00f6rgensen L, Johansson G, Larsson K. COPD health care in Sweden: a study in primary and secondary care. Respir Med. 2010;104:404\u201311. https:\/\/doi.org\/10.1016\/j.rmed.2009.10.007.","journal-title":"Respir Med"},{"key":"1408_CR18","unstructured":"World Health Organization. Number of physicians, medical group of specialties (PP). 2023. https:\/\/gateway.euro.who.int\/en\/indicators\/hfa_499-5261-number-of-physicians-medical-group-of-specialties-pp\/. Accessed 1 Mar 2024."},{"key":"1408_CR19","unstructured":"Madison T, Arias A, DiSantostefano R, Gilsenan A, Matus D, Primatesta P, et al. Evaluating the effectiveness of additional risk minimisation measures via surveys in Europe: challenges and recommendations. 2016. https:\/\/pharmacoepi.org\/pub\/?id=f46953df-de69-31e7-8f74-725bd7fa685f. Accessed 1 Mar 2024."},{"key":"1408_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/14740338.2019.1612875","volume":"18","author":"E Artime","year":"2019","unstructured":"Artime E, Qizilbash N, Garrido-Estepa M, Vora P, Soriano-Gabarr\u00f3 M, Asiimwe A, et al. Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opin Drug Saf. 2019;18:443\u201354. https:\/\/doi.org\/10.1080\/14740338.2019.1612875.","journal-title":"Expert Opin Drug Saf"},{"key":"1408_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/0163278713496425","volume":"36","author":"YI Cho","year":"2013","unstructured":"Cho YI, Johnson TP, VanGeest JB. Enhancing surveys of health care professionals: a meta-analysis of techniques to improve response. Eval Health Prof. 2013;36:382\u2013407. https:\/\/doi.org\/10.1177\/0163278713496425.","journal-title":"Eval Health Prof"},{"key":"1408_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1472-6963-9-160","volume":"9","author":"JV Cook","year":"2009","unstructured":"Cook JV, Dickinson HO, Eccles MP. Response rates in postal surveys of healthcare professionals between 1996 and 2005: an observational study. BMC Health Serv Res. 2009;9:160. https:\/\/doi.org\/10.1186\/1472-6963-9-160.","journal-title":"BMC Health Serv Res"},{"key":"1408_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/cpt.3034","volume":"114","author":"RJ Grupstra","year":"2023","unstructured":"Grupstra RJ, Goedecke T, Scheffers J, Strassmann V, Gardarsdottir H. Review of studies evaluating effectiveness of risk minimization measures assessed by the European Medicines Agency between 2016 and 2021. Clin Pharmacol Ther. 2023;114:1285\u201392. https:\/\/doi.org\/10.1002\/cpt.3034.","journal-title":"Clin Pharmacol Ther"},{"key":"1408_CR24","unstructured":"European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module XVI: risk minimisation measures: selection of tools and effectiveness indicators (Rev 3). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators-rev-3_en.pdf. Accessed 1 Mar 2024."},{"key":"1408_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1503\/cmaj.080372","volume":"179","author":"KEA Burns","year":"2008","unstructured":"Burns KEA, Duffett M, Kho ME, Meade MO, Adhikari NKJ, Sinuff T, et al. A guide for the design and conduct of self-administered surveys of clinicians. Can Med Assoc J. 2008;179:245\u201352. https:\/\/doi.org\/10.1503\/cmaj.080372.","journal-title":"Can Med Assoc J"},{"key":"1408_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12874-015-0016-z","volume":"15","author":"CT Cunningham","year":"2015","unstructured":"Cunningham CT, Quan H, Hemmelgarn B, Noseworthy T, Beck CA, Dixon E, et al. Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol. 2015;15:32. https:\/\/doi.org\/10.1186\/s12874-015-0016-z.","journal-title":"BMC Med Res Methodol"},{"key":"1408_CR27","unstructured":"US Food and Drug Administration. Opioid analgesic risk evaluation and mitigation strategy (REMS). 2023. https:\/\/www.fda.gov\/drugs\/information-drug-class\/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems. Accessed 1 Mar 2024."},{"key":"1408_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/chp.1340230305","volume":"23","author":"MK Robertson","year":"2003","unstructured":"Robertson MK, Umble KE, Cervero RM. Impact studies in continuing education for health professions: update. J Contin Educ Health Prof. 2003;23:146\u201356. https:\/\/doi.org\/10.1002\/chp.1340230305.","journal-title":"J Contin Educ Health Prof"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01408-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:09:41Z","timestamp":1734016181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01408-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01408-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"29 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer. Medical writing support was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Joanne Wu, Nana Koram, Kofi Asomaning and Edward Nagy are employees and stockholders of Pfizer Inc. Lubna Merchant\u00a0is an employee of Pfizer Inc. Robert\u00a0Massouh is a former employee and current stockholder of Pfizer\u00a0Inc, and an employee and current stockholder of GSK. Subhan Khalid, Laura Walsh, Rafia Bosan and Krystal Cantos are employees of IQVIA, who were paid contractors to Pfizer in the development of this article and in providing statistical support.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Independent ethics committee\/institutional review board review was not required in any of the study countries and a waiver was received from a German independent ethics committee. All prescribers who chose to participate provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See  for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KA, RM and LW conceived\/designed the study. JW, KA, LW, RB and KC acquired the data. JW, NK, LM, EN, SK, LW, RB and KC analysed the data. JW, NK, KA, LM, RM, EN, SK, LW, RB and KC interpreted the data. All authors drafted the work or revised it critically for important intellectual content, gave final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}